The Director, BD Early Stage leads the assessment of earl y- stage external innovation opportunities from Due Diligence Stage 2 to negotiation of a Non-Binding Offer ( NBO ) . The role integrates evolving scientific advances, therapeutic trends and market dynamics to guide CSL's long-range BD investment decisions in early - stage opportunities. It provides deep subject-matter leadership and enterprise-level judgement to ensure potential partnerships and acquisitions advance CSL’s portfolio impact, scientific differentiation and competitive positioning. Responsibilities & Accountabilities External Innovation Evaluation Leadership: Lead evaluation of early-stage external assets, technologies, platforms and modalities aligned to TA Strategy from Due Diligence Stage 2 through Governance to negotiation of NBO. Integrate scientific, clinical, mechanistic, regulatory and commercial evidence into holistic assessments of attractiveness, differentiation and enterprise and TA strategic fit. Development of Investment-Ready Assessments: Deliver investment-quality inputs such as valuation assumptions, scenario modelling, unmet need assessments, deal analogues and downstream implications (e.g., biomarker requirements, specialized development pathways, manufacturing needs). Translate complex scientific and clinical narratives into clear, concise and decision-ready recommendations for CSL senior leaders. Strategic Judgement and Opportunity Prioritization: Provide recommendations on progressing, deferring or declining opportunities based on enterprise priorities and the TA Strategy. Apply CSL’s evaluation standards and prioritization frameworks to ensure rigor, consistency and balanced risk-benefit assessment. Cross-Functional Partnership and Collaboration: Develop and maintain key external partnerships with potential partners in close collaboration with R&D Search. Partner with BD Transactions to shape valuation logic, risk scenarios, deal structures and diligence readiness for adva